Products
Adakitug Biosimilar Monoclonal Antibody (IL-8) for Research
Cat No.: GMP-Bios-INN-1065
Anti-CXCL8 therapeutic antibody (Pre-made Adakitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Adakitug (development code BMS-986253) is a monoclonal antibody targeting CXCL8 (IL-8). It is developed by Bristol-Myers Squibb for colon sarcoma, myelodysplastic syndromes, gastric adenocarcinoma. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1065-1mg | 1mg | 3090 |
| GMP-Bios-INN-1065-10mg | 10mg | |
| GMP-Bios-INN-1065-100mg | 100mg | |
| GMP-Bios-INN-1065-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Adakitug biosimilar, Whole mAb, Anti-CXCL8 Antibody: Anti-CXCL8/IL-8/IL8/Interleukin-8 therapeutic antibody |
| INN Name | Adakitug |
| Target | CXCL8 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Bristol-Myers Squibb |
| Conditions Approved | na |
| Conditions Active | Colon sarcoma;Myelodysplastic syndromes;Gastric adenocarcinoma |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
